The leading enterprise of innovative medicine is expected to achieve "overtaking on the curve"

"Consistency evaluation", "volume purchase", "new drug review and approval addenda" In 2018, driven by these policies, many reforms took place in China's pharmaceutical industry, and the overall integration of the industry accelerated The industry believes that after this wave, in addition to the stable survival of those enterprises with high-quality drugs, the leading enterprises of innovative drugs will also be expected to achieve "detour overtaking" (the pharmaceutical industry is full of waves, who can overtake at the corner?) Market pattern changes by the end of this year, the "4 + 7 urban drug centralized procurement document" was officially released, which means that the "volume procurement" work has been started, and the 11 cities involved will be centralized bidding procurement pilot varieties The industry believes that the result of bidding may be the basis for the formulation of pharmaceutical payment price and further effectively reduce the drug price This also means that at that time, the pharmaceutical market will take on a new pattern, and varieties with high quality and reasonable cost can benefit for a long time At the same time, the trend of drug market in 2018 will be continued Innovative drugs and generic drugs will pay equal attention to the pattern, and innovative drugs will be added to the market And with the expiration of a batch of drugs, there will be fierce competition for generic drugs, squeezing the situation of high price expired drugs In this context, on the one hand, expired drugs will be "excluded" from the market, on the other hand, the generic pharmaceutical industry will also be shuffled, and the generic pharmaceutical enterprises have more competitive advantages The industry concentration will continue to improve in 2019, while the pharmaceutical market pattern changes, the industry integration is also accelerating, and the industry concentration will continue to improve According to the industry, in the field of medical services, enterprises with rich resources are favored after shuffling In the pharmaceutical retail sector, the hierarchical management of drugstores is conducive to the integration of the industry and the improvement of the industry concentration Drugstores with strength are expected to achieve better development In addition, in the pharmaceutical industry, generic competition will lead to lower drug prices, and with the change of medical insurance structure, drugs and innovative drugs will be favored in the future Pharmaceutical companies with strong R & D capability and innovation are expected to expand market share The future development of the industry is good Although China's pharmaceutical industry has experienced a lot in 2018, one of the themes of the recent "2018 China Pharmaceutical Capital Forum" is "this year's winter of pharmaceutical investment industry is colder than previous years" It can be seen that the pharmaceutical investment has become more rational, and at present it is more of a wait-and-see state But the industry remains confident in the pharmaceutical industry for some time to come First, demand continues to expand China is a country with a large population, and with the development of economy and scientific progress, the life expectancy of our country is greatly increased, and the aging population is accelerating, which also makes the rigid demand of the pharmaceutical industry increase And with the introduction of medical insurance policy, people will still yearn for drug treatment, or even some more medical products Second, from the results of the first three quarters of 2018, the growth rate in the third quarter slowed down and tended to be normal The industry believes that the industry is still expected to continue the growth trend in 2019 Third, the supply side reform under the regulation of pharmaceutical policy will make the pharmaceutical industry move forward steadily in the development According to the industry, the current pharmaceutical industry has entered a new boom cycle, with innovative drugs and excellent high-quality drugs receiving major attention, the concentration of the pharmaceutical industry is also constantly improving, and the relevant leading pharmaceutical enterprises are strong In addition, the market pattern has been changing, and the next step is to speed up the listing of innovative drugs and the substitution of generic drugs for imports R & D driven pharmaceutical companies and enterprises with strength will usher in favorable policies.